Artelo biosciences announces publication of positive non-clinical fatty acid binding protein 5

Artelo biosciences, inc. announced that positive non-clinical data with the company’s fatty acid binding protein 5 (fabp5) inhibitor program under development in collaboration with the research foundation of the state university of new york stony brook, were published in the october 2019 issue of the prostate, a premier peer-reviewed journal. prostate cancer remains the second leading cause of cancer-related death among men. taxanes, such as docetaxel and cabazitaxel are utilized in standard treatment regimens for chemotherapy naÏve castration-resistant prostate cancers. however, tumors often develop resistance to taxanes, and taxane-treatment can lead to numerous adverse effects that can lead to the termination of therapy. fabp5 is an intra-cellular protein chaperone that serves as a carrier for fatty acids that trigger increased expression of genes associated with tumor angiogenesis and reduced patient survival. inhibition of fabp5 has previously been shown to suppresses the growth and migration of breast and prostate cancers. researchers at stony brook university assessed whether fabp5 inhibitors synergize with semi-synthetic taxanes to induce cytotoxicity in vitro and attenuate tumor growth in vivo.
ARTL Ratings Summary
ARTL Quant Ranking